Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics (Nasdaq: ELYM) has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit, scheduled for September 17-18, 2024.

Rhea-AI Summary

Eliem Therapeutics (Nasdaq: ELYM) has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit, scheduled for September 17-18, 2024. The company's management team will be available for one-on-one meetings on Wednesday, September 18, 2024.

Eliem Therapeutics is a biopharmaceutical company focused on developing treatments for autoimmune-driven inflammatory diseases. Their lead candidate, budoprutug, is an anti-CD19 antibody designed to address a range of autoimmune conditions, including:

• Systemic lupus erythematosus
• Lupus nephritis
• Immune thrombocytopenia
• Membranous nephropathy

Investors interested in more information can contact Chris Brinzey at ICR Westwicke.

Argus Session date unavailable

+0.64% session move Open Argus

Details

News Market Reaction – ELYM

The recorded move for ELYM in the trading session of this news was +0.64%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.

Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Format: 1x1 meetings

About Eliem Therapeutics, Inc.
Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit https://eliemtx.com/.

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Eliem Therapeutics participating in the Stifel 2024 Virtual Immunology and Inflammation Summit?

Eliem Therapeutics (ELYM) is participating in the Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024.

What is the format of Eliem Therapeutics' participation in the Stifel 2024 summit?

Eliem Therapeutics (ELYM) will be participating in one-on-one meetings during the Stifel 2024 Virtual Immunology and Inflammation Summit.

What is Eliem Therapeutics' main focus in drug development?

Eliem Therapeutics (ELYM) is focused on developing therapeutics for autoimmune-driven inflammatory diseases, with their lead candidate budoprutug targeting conditions like systemic lupus erythematosus and immune thrombocytopenia.

What is budoprutug and what conditions does it target?

Budoprutug is an anti-CD19 antibody developed by Eliem Therapeutics (ELYM) for a range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.